Cancer Research 2010 AACR Elections 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carboni, J. M.
Right arrow Articles by Wong, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carboni, J. M.
Right arrow Articles by Wong, T. W.
[Cancer Research 65, 3781-3787, May 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor

Joan M. Carboni1, Adrian V. Lee3, Darryl L. Hadsell4, Bruce R. Rowley1, Francis Y. Lee1, David K. Bol1, Amy E. Camuso1, Marco Gottardis1, Ann F. Greer1, Ching Ping Ho1, Warren Hurlburt1, Aixin Li1, Mark Saulnier5, Upender Velaparthi5, Cindy Wang1, Mei-Li Wen1, Richard A. Westhouse2, Mark Wittman5, Kurt Zimmermann5, Brent A. Rupnow1 and Tai W. Wong1

1 Oncology Drug Discovery and 2 Discovery Toxicology, Bristol-Myers Squibb Research Institute, Princeton, New Jersey; 3 The Breast Center and 4 The Children's Nutrition and Research Center, Departments of Medicine, Pediatrics, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas; and 5 Discovery Chemistry, Bristol-Myers Squibb Research Institute, Wallingford, Connecticut

Requests for reprints: Tai W. Wong, Pharm Research Institute Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ 08534. Phone: 609-252-4187; Fax: 609-252-6171; E-mail: tai.wong{at}bms.com.

The insulin-like growth factor I receptor (IGF-IR) is a transmembrane tyrosine kinase that is essential to growth and development and also thought to provide a survival signal for the maintenance of the transformed phenotype. There has been increasing interest in further understanding the role of IGF-I signaling in cancer and in developing receptor antagonists for therapeutic application. We describe herein a novel animal model that involves transgenic expression of a fusion receptor that is constitutively activated by homodimerization. Transgenic mice that expressed the activated receptor showed aberrant development of the mammary glands and developed salivary and mammary adenocarcinomas as early as 8 weeks of age. Xenograft tumors and a cell line were derived from the transgenic animals and are sensitive to inhibition by a novel small-molecule inhibitor of the IGF-IR kinase. This new model should provide new opportunities for further understanding how aberrant IGF-IR signaling leads to tumorigenesis and for optimizing novel antagonists of the receptor kinase.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
C. Hantel, F. Lewrick, S. Schneider, O. Zwermann, A. Perren, M. Reincke, R. Suss, and F. Beuschlein
Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency
J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 943 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. M. Carboni, M. Wittman, Z. Yang, F. Lee, A. Greer, W. Hurlburt, S. Hillerman, C. Cao, G. H. Cantor, J. Dell-John, et al.
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Mol. Cancer Ther., December 1, 2009; 8(12): 3341 - 3349.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cadieux, V. Kedinger, L. Yao, C. Vadnais, M. Drossos, M. Paquet, and A. Nepveu
Mouse Mammary Tumor Virus p75 and p110 CUX1 Transgenic Mice Develop Mammary Tumors of Various Histologic Types
Cancer Res., September 15, 2009; 69(18): 7188 - 7197.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. M. Rowzee, D. L. Ludwig, and T. L. Wood
Insulin-Like Growth Factor Type 1 Receptor and Insulin Receptor Isoform Expression and Signaling in Mammary Epithelial Cells
Endocrinology, August 1, 2009; 150(8): 3611 - 3619.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
O. P. Rogozina, M. J.L. Bonorden, J. P. Grande, and M. P. Cleary
Serum Insulin-like Growth Factor-I and Mammary Tumor Development in Ad libitum-Fed, Chronic Calorie-Restricted, and Intermittent Calorie-Restricted MMTV-TGF-{alpha} Mice
Cancer Prevention Research, August 1, 2009; 2(8): 712 - 719.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Berlato and W. Doppler
Selective Response to Insulin Versus Insulin-Like Growth Factor-I and -II and Up-Regulation of Insulin Receptor Splice Variant B in the Differentiated Mouse Mammary Epithelium
Endocrinology, June 1, 2009; 150(6): 2924 - 2933.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. L. Kleinberg, T. L. Wood, P. A. Furth, and A. V. Lee
Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions
Endocr. Rev., February 1, 2009; 30(1): 51 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. C. Litzenburger, H.-J. Kim, I. Kuiatse, J. M. Carboni, R. M. Attar, M. M. Gottardis, C. R. Fairchild, and A. V. Lee
BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells
Clin. Cancer Res., January 1, 2009; 15(1): 226 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y.C. Wang, A. L. Stratford, E. Park, J. M.W. Gee, P. Finlay, H. E. Jones, et al.
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
Cancer Res., December 15, 2008; 68(24): 10238 - 10246.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Ann. Onc., November 1, 2008; 19(11): 1860 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. K. de Ostrovich, I. Lambertz, J. K. L. Colby, J. Tian, J. E. Rundhaug, D. Johnston, C. J. Conti, J. DiGiovanni, and R. Fuchs-Young
Paracrine Overexpression of Insulin-Like Growth Factor-1 Enhances Mammary Tumorigenesis in Vivo
Am. J. Pathol., September 1, 2008; 173(3): 824 - 834.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. A. Jones, C. I. Campbell, J. J. Petrik, and R. A. Moorehead
Characterization of a Novel Primary Mammary Tumor Cell Line Reveals that Cyclin D1 Is Regulated by the Type I Insulin-Like Growth Factor Receptor
Mol. Cancer Res., May 1, 2008; 6(5): 819 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. C. Carver and L. A. Schuler
Prolactin Does Not Require Insulin-Like Growth Factor Intermediates but Synergizes with Insulin-Like Growth Factor I in Human Breast Cancer Cells
Mol. Cancer Res., April 1, 2008; 6(4): 634 - 643.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. D. Ryan and P. E. Goss
The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer
Oncologist, January 1, 2008; 13(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar
Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4291 - 4299.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
H.-J. Kim, B. C. Litzenburger, X. Cui, D. A. Delgado, B. C. Grabiner, X. Lin, M. T. Lewis, M. M. Gottardis, T. W. Wong, R. M. Attar, et al.
Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-{kappa}B and Snail
Mol. Cell. Biol., April 15, 2007; 27(8): 3165 - 3175.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D.S. Fernandez-Twinn, S. Ekizoglou, B.A. Gusterson, J. Luan, and S.E. Ozanne
Compensatory mammary growth following protein restriction during pregnancy and lactation increases early-onset mammary tumor incidence in rats
Carcinogenesis, March 1, 2007; 28(3): 545 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. K. Dearth, X. Cui, H.-J. Kim, I. Kuiatse, N. A. Lawrence, X. Zhang, J. Divisova, O. L. Britton, S. Mohsin, D. C. Allred, et al.
Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2
Mol. Cell. Biol., December 15, 2006; 26(24): 9302 - 9314.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A M Lorincz and S Sukumar
Molecular links between obesity and breast cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 279 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
T. Vargo-Gogola, B. M. Heckman, E. J. Gunther, L. A. Chodosh, and J. M. Rosen
P190-B Rho GTPase-Activating Protein Overexpression Disrupts Ductal Morphogenesis and Induces Hyperplastic Lesions in the Developing Mammary Gland
Mol. Endocrinol., June 1, 2006; 20(6): 1391 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. A. Kellar, M. V. Lorenzi, C. P. Ho, D. You, M.-L. Wen, R. P. Ryseck, S. Oppenheimer, B. E. Fink, G. D. Vite, B. R. Rowley, et al.
Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics.
Mol. Cancer Ther., June 1, 2006; 5(6): 1571 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Haluska, J. M. Carboni, D. A. Loegering, F. Y. Lee, M. Wittman, M. G. Saulnier, D. B. Frennesson, K. R. Kalli, C. A. Conover, R. M. Attar, et al.
In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417
Cancer Res., January 1, 2006; 66(1): 362 - 371.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Miller and D. Yee
Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer
Cancer Res., November 15, 2005; 65(22): 10123 - 10127.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.